| In millions, except per share items | Mar-31-22 | Mar-31-21 | Mar-31-20 | Mar-31-19 | Mar-31-18 | Mar-31-17 | Mar-31-16 | Mar-31-15 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Europe | 6.7 | 7.2 | | | | | | |
| Exeltis | | | | | | | | 0.4 |
| Laboratorios Sanfer | | | | | | | | 1.5 |
| Other | 5.9 | 11.4 | | | | | | 11.9 |
| Total revenues [+] | 12.6 | 18.6 | 17.9 | 19.0 | 16.7 | 12.8 | 9.4 | 13.9 |
| Licensing | | | | | | | 0.2 | 3.1 |
| Products | | | | | | | 8.1 | 9.9 |
| Services | | | | | | | 1.1 | 0.9 |
| Revenue growth [+] | -32.2% | 3.9% | -5.5% | 13.9% | 29.9% | 36.9% | -32.4% | 1.4% |
| Europe | -7.0% | | | | | | | |
| Exeltis | | | | | | | | -45.8% |
| Laboratorios Sanfer | | | | | | | | -0.1% |
| Innovacyn | | | | | | | | -63.9% |
| Cost of goods sold [+] | 9.4 | 12.1 | 9.8 | 10.1 | 9.3 | 7.2 | 6.7 | 6.6 |
| Cost of product sales | | | | | | | 5.8 | 5.9 |
| Cost of services | | | | | | | 0.9 | 0.7 |
| Gross profit | 3.2 | 6.6 | 8.1 | 8.9 | 7.3 | 5.7 | 2.6 | 7.3 |
| Gross margin | 25.5% | 35.2% | 45.3% | 46.8% | 43.9% | 44.2% | 28.3% | 52.6% |
| Selling, general and administrative | 9.8 | 9.5 | 14.2 | 18.6 | 19.9 | 17.1 | 15.6 | 12.4 |
| Research and development | 0.1 | 0.6 | 1.3 | 1.5 | 1.6 | 1.6 | 1.8 | 1.5 |
| Other operating expenses | -0.8 | | | | | | | |
| EBITDA [+] | -5.7 | -3.2 | -7.1 | -10.8 | -13.7 | -12.7 | -14.5 | -6.4 |
| EBITDA growth | 76.9% | -54.5% | -34.5% | -21.1% | 7.6% | -12.1% | 125.9% | -219.4% |
| EBITDA margin | -45.1% | -17.3% | -39.5% | -57.0% | -82.2% | -99.2% | -154.4% | -46.2% |
| Depreciation and amortization | 0.2 | 0.2 | 0.3 | 0.5 | 0.5 | 0.2 | 0.2 | 0.3 |
| EBIT [+] | -5.9 | -3.4 | -7.4 | -11.3 | -14.2 | -13.0 | -14.7 | -6.7 |
| EBIT growth | 70.7% | -53.3% | -34.4% | -20.7% | 9.4% | -11.8% | 121.0% | -231.0% |
| EBIT margin | -46.6% | -18.5% | -41.2% | -59.3% | -85.2% | -101.2% | -157.0% | -48.1% |
| Interest income, net [+] | 0.0 | 0.0 | 0.0 | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 |
| Interest expense | 0.0 | | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Interest income | | 0.0 | 0.1 | 0.2 | 0.3 | 0.0 | 0.0 | 0.0 |
| Other income (expense), net [+] | 0.5 | -0.5 | 3.8 | -0.2 | -0.3 | 0.0 | 0.0 | -1.5 |
| Gain (loss) on sale of assets | 0.2 | 0.1 | 3.6 | | | | | |
| Gain (loss) on investments | | | | | | | | -4.7 |
| Unrealized gain/loss on derivatives | | | | | | | 0.0 | 3.2 |
| Other non-ooperating expenses | | | | | | | | -0.1 |
| Other | | | | | | | | 0.1 |
| Pre-tax income | -5.4 | -3.9 | -3.5 | -11.3 | -14.3 | -12.9 | -14.7 | -8.2 |
| Income taxes | -0.3 | 0.7 | 0.0 | 0.5 | 0.1 | -4.3 | 0.0 | 0.0 |
| Tax rate | 6.1% | | | | | 33.0% | 0.0% | 0.0% |
| Earnings from continuing ops | -5.1 | -5.3 | -3.6 | -11.8 | -14.3 | -26.6 | -19.3 | -8.2 |
| Earnings from discontinued ops | | 0.7 | 0.3 | | | 17.9 | 4.6 | |
| Net income | -5.1 | -4.6 | -3.3 | -11.8 | -14.3 | -8.7 | -14.7 | -8.2 |
| Net margin | -40.3% | -24.8% | -18.5% | -62.2% | -86.0% | -67.6% | -157.2% | -59.2% |
| |
| Basic EPS [+] | ($1.92) | ($2.65) | ($2.42) | ($12.77) | ($28.49) | ($6.30) | ($5.86) | ($0.85) |
| Growth | -27.5% | 9.4% | -81.1% | -55.2% | 352.1% | 7.4% | 590.3% | -256.5% |
| Diluted EPS [+] | ($1.92) | ($2.65) | ($2.42) | ($12.77) | ($28.49) | ($6.30) | ($5.86) | ($0.85) |
| Growth | -27.5% | 9.4% | -81.1% | -55.2% | 352.1% | 7.4% | 590.3% | -256.9% |
| |
| Shares outstanding (basic) [+] | 2.7 | 2.0 | 1.5 | 0.9 | 0.5 | 4.2 | 3.3 | 9.7 |
| Growth | 32.9% | 35.1% | 59.8% | 83.7% | -88.1% | 28.4% | -65.9% | 40.3% |
| Shares outstanding (diluted) [+] | 2.7 | 2.0 | 1.5 | 0.9 | 0.5 | 4.2 | 3.3 | 9.7 |
| Growth | 32.9% | 35.1% | 59.8% | 83.7% | -88.1% | 28.4% | -65.9% | 40.0% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |